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Hepatitis E virus (HEV) is an important etiological agent of epidemic and sporadic hepatitis, which is
endemic to the Indian subcontinent and prevalent in most of the developing parts of the world. The infection
is often associated with acute liver failure and high mortality, particularly in pregnant women. In order to
develop methods of intervention, it is essential to understand the biology of the virus. This is particularly
important as no reliable in vitro culture system is available. We have constructed a cDNA clone encompassing
the complete HEV genome from independently characterized subgenomic fragments of an Indian epidemic
isolate. Transfection studies were carried out with HepG2 cells using in vitro-transcribed RNA from this
full-length HEV cDNA clone. The presence of negative-sense RNA, indicative of viral replication, was demon-
strated in the transfected cells by strand-specific reverse transcription-PCR and slot blot hybridization. The
viral proteins pORF2 and pORF3 and processed components of the pORF1 polyprotein (putative methyltrans-
ferase, helicase, and RNA-dependent RNA polymerase) were identified in the transfected cells by metabolic
pulse-labeling with [35S]methionine-cysteine, followed by immunoprecipitation with respective antibodies. The
expression of viral proteins in the transfected cells was also demonstrated by immunofluorescence microscopy.
Viral replication was detected in the transfected cells up to 33 days posttransfection (six passages). The culture
supernatant from the transfected cells was able to produce HEV infection in a rhesus monkey (Macaca mulatta)
following intravenous injection, indicating the generation of viable HEV particles following transfection of cells
with in vitro-synthesized genomic RNA. This transient cell culture model using in vitro-transcribed RNA
should facilitate our understanding of HEV biology.
Hepatitis E virus (HEV) is established as an etiological
agent of the epidemic and sporadic forms of waterborne hep-
atitis (6, 25). The first well-characterized HEV epidemic was
reported in Delhi, India, in 1955 (35). Several other epidemics
have since been described in developing countries on nearly
every continent (19, 21). HEV has a positive-strand polyade-
nylated RNA genome ;7.2 kb in length (27) containing three
open reading frames (ORFs). Nonstructural ORF1 (59 end)
codes for a polyprotein of 1,693 amino acids (pORF1) and
contain domains homologous to a viral methyltransferase, a
papainlike cysteine protease, an RNA helicase, and an RNA-
dependent RNA polymerase (RdRp). The second ORF (39
end) codes for the major viral capsid protein of 660 amino acid
(pORF2), while the third and smallest ORF (ORF3) codes for
a 123-amino-acid-long polypeptide (pORF3) whose function is
unknown (32). Apart from its coding region, the viral genome
has 27- and 68-nucleotide (nt)-long noncoding regions at its 59
and 39 ends, respectively (32). The genome sequences of HEV
have been reported from different geographical isolates and
show a high degree of homology at both the nucleotide and
amino acid levels (3, 4, 12, 32, 33). Expression of structural
proteins pORF2 and pORF3 in prokaryotic and eukaryotic
systems has been reported by different investigators (7, 11, 14,
23, 29). Earlier, we have expressed and characterized pORF2
and pORF3 in animal cells. pORF2 is an 88-kDa glycoprotein
which is expressed intracellularly, as well as on the cell surface
(14, 37). The ORF3 protein (pORF3) is a 13.5-kDa phospho-
protein which is phosphorylated by the cellular mitogen-acti-
vated protein kinase and associates with the cytoskeleton (36).
We have also recently expressed the ORF1 polyprotein in both
prokaryotic and eukaryotic systems (2).
In the absence of a reliable in vitro culture system, the
replication and transcription strategy of HEV is poorly under-
stood. The in vitro propagation and production of HEV from
the primary hepatocytes of experimentally infected cynomol-
gus macaques has been reported (31). However, this is of
limited utility due to difficulties associated with animal exper-
imentation. Several cDNA clones of other positive-strand
RNA viruses have been shown to be infectious in cell culture
and experimental animal systems (9, 26). In the present study,
we have analyzed the potential of a full-length, in vitro-synthe-
sized HEV RNA from a cDNA clone of an Indian isolate of
HEV. We demonstrate here the replication and expression of
HEV from this RNA in cultured hepatoma cells, as well as the
production of infectious virions ascertained through experi-
mental infection of a rhesus macaque.
MATERIALS AND METHODS
Assembly of a full-length HEV cDNA clone. The three known ORFs (GenBank
accession no. AF028091 [ORF1] and U22532 [ORF2 and ORF3]), along with the
noncoding regions from an epidemic isolate of HEV from India, have been
cloned by us using subgenomic PCR amplification followed by a reconstruction
strategy (2, 14). We have expressed these fragments in both prokaryotic and
eukaryotic systems (2, 14, 23). These subgenomic fragments were produced by
PCR cloning and assembly from a single viral isolate grown in a rhesus monkey.
These previously described cloned fragments were used for the reconstruction of
a full-length genomic cDNA clone of HEV. Briefly, an XhoI restriction enzyme
site was engineered in the primer 7195 sequence (59GCctcgagTTTTTCAGGG
AGCGCGGAACGCA39) that had a stretch of five thymidine bases at the 39 end
to produce an ORF2-pBluescript SK(1) (Stratagene) clone. This clone was
extended at the 59 end by inserting a PCR-amplified fragment of HEV covering
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4,438 to 5,285 nt using a standard cloning procedure. The HEV clone ORF1-
pSGI was digested with EcoRI and XbaI to release an insert ranging from nt 1
to nt 4449, whereas the insert ranging from nt 4449 to nt 7195 was released from
the nt 4438 to nt 7195 pBluescript SK(1) clone by digestion with restriction
enzymes XbaI and XhoI. These inserts were cloned into a pSGI vector (13)
digested with restriction enzymes EcoRI and XhoI in a three-way ligation. A
schematic representation of the reconstruction is given in Fig. 1. This full-length
HEV cDNA clone was completely sequenced after reconstruction and named
pSGI-HEV(I).
In vitro transcription of full-length HEV RNA. In vitro transcription of the
above-described cDNA clone [pSGI-HEV(I)] was carried out using T7 RNA
polymerase (Stratagene) to generate full-length HEV transcripts. Briefly, the
CsCl2 gradient-purified plasmid [pSGI-HEV(I)] containing the full-length HEV
cDNA was digested with XhoI to produce a linear DNA template. RNA was
transcribed in vitro using 50 U of T7 RNA polymerase in a 50-ml reaction volume
containing 40 mM Tris-HCl (pH 8.0), 8 mM MgCl2, 50 mM NaCl, 2 mM
spermidine, 30 mM dithiothreitol, 400 mM each ribonucleoside triphosphate,
and 5 mg of template DNA. The reaction mixture was incubated at 37°C for 30
min and then digested with DNase I (RQ1 RNase-free DNase; Promega) for 1 h
at 37°C. The reaction mixture was extracted with phenol-chloroform and then
subjected to a second round of DNase I digestion and phenol-chloroform ex-
traction to ensure no carryover of the template DNA with the transcripts. The
transcripts were ethanol precipitated at 270°C for 1 h. The RNA pellet was
washed with cold 70% ethanol and dried, and its integrity was analyzed by 0.8%
formaldehyde agarose gel electrophoresis, followed by ethidium bromide stain-
ing and Northern hybridization (Fig. 2).
In vitro-produced RNA was resolved on a 0.8% formaldehyde denaturing
agarose gel and transferred to nylon membrane (Hybond; Amersham Interna-
tional) in the presence of 203 SSC (13 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate). The membrane was washed with a 103 SSC solution, air dried, and
subjected to UV cross-linking in a UV cross-linker (Stratagene). The membrane
was put in a prehybridization solution (63 SSC, 53 Denhardt’s solution, 0.5%
sodium dodecyl sulfate [SDS], 100 mg of calf thymus DNA per ml of solution)
and incubated at 68°C for 6 h in a hybridization oven (Shel Lab model 1004). The
hybridization was subsequently carried out in a fresh prehybridization solution
containing 107 cpm of an [a-32P]dCTP-labeled probe generated from the full-
length ORF2 clone of HEV (22). The probe was prepared by using a commercial
random priming kit (Prime-it; Stratagene) in accordance with the manufacturer’s
protocol. Following hybridization for 16 h at 68°C, the membrane was washed as
follows: (i) once in 23 SSC–0.1% SDS for 5 min at room temperature, (ii) twice
in 0.23 SSC–0.1% SDS for 5 min at room temperature, (iii) once in 0.23
SSC–0.1% SDS for 15 min at 42°C, and (iv) once in 0.13 SSC–0.1% SDS for 15
min at 68°C.
All of the solutions were discarded as radioactive waste. Following the last
wash, the membrane was wrapped in Saran Wrap and exposed to autoradiogra-
phy using Kodak X-Omat AR film with Du Pont intensifying screens.
RNA transfection and metabolic pulse-labeling. HepG2 cells were maintained
in Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum (Life
Technologies). Cells at ;50% confluency were used for transfection of HEV
RNA. Twenty micrograms of in vitro-produced RNA was transfected by a lipo-
some induction method (Lipofectamine; Life Technologies) in accordance with
the manufacturer’s guidelines. The plasmid vector (pSGI) served as a control for
the transfection. For each 60-mm-diameter culture dish, 20 mg of the HEV RNA
and 10 ml of Lipofectamine were diluted in 1.5 ml of serum-free medium. The
mixture was kept at room temperature for 30 min and gently overlaid onto the
monolayer. Fresh medium with 10% fetal calf serum was added after 6 h, and the
cells were kept in an atmosphere of 5% CO2. After 72 h, the cells were harvested
for extraction of total RNA.
Transfected cells were pulse-labeled (100 mCi/ml/60-mm-diameter plate) with
[35S]methionine-cysteine (Promix; Amersham International) for 4 h at 72 h
posttransfection in methionine-cysteine-deficient Dulbecco’s modified Eagle’s
medium (Sigma). The metabolically labeled cells were harvested, and proteins
were immunoprecipitated using HEV-specific polyclonal antibodies. Similar la-
beling experiments were also carried out at 12, 24, 36, 72, and 96 h to determine
the expression kinetics of the viral RdRp. A batch of the HEV RNA-transfected
cells was maintained in the culture and allowed to grow for the next 45 days
(eight passages). These cells were analyzed at 3, 7, 15, 33, and 45 days posttrans-
fection for the presence of antisense RNA replicative intermediates using strand-
specific PCR.
Detection of antisense HEV RNA. Strand-specific PCR was carried out to
detect antisense and sense HEV RNAs in the transfected cells (20). Total RNA
from the cells was isolated at days 3, 7, 15, 33, and 45 posttransfection by a
single-step RNA isolation method (8). A serial log fold dilution of the total RNA
extracted at 72 h (3 days) was carried out to determine an approximate ratio of
sense and antisense strands. For sense strand detection, the HepG2 cells trans-
fected with plasmid pSGI and serum from an HEV-infected monkey with viremia
served as negative and positive controls, respectively. For antisense strand de-
tection, RNA isolated from an HEV-infected monkey liver containing an anti-
sense replicative intermediate served as a positive control whereas bile fluid or
serum from the same viremic animal served as a negative control. For strand-
specific detection, reverse transcription (RT) was carried out using either a sense
or an antisense primer. Following cDNA synthesis, the RNA in the reaction
mixture was degraded by digestion with RNase H (2 U) and RNase A (1 mg;
Promega). Following RNase treatment, the reaction mixture was extracted once
with phenol-chloroform and ethanol precipitated. The precipitated cDNA was
used for PCR amplification using both sense and antisense primers.
For hybridization-based detection, total RNA (30 mg) extracted from the
transfected cells was immobilized on a nylon membrane (Amersham Interna-
FIG. 1. Schematic representation of the strategy used to assemble a full-length HEV cDNA clone. The ORF2 pCR-Script SK(1) clone was extended at its 59 end
with a PCR-amplified fragment (nt 4438 to 5285) using inherent BstEII and XbaI restriction sites. An XhoI site was created at the 39 end using another PCR-amplified
fragment with the XhoI site in the primer, which replaced a fragment extending from nt 6881 to 7195. This fragment (nt 4449 to 7195) and the fragment of ORF1 (nt
1 to 4449) were used in a three-way ligation to create the complete cDNA clone of HEV [pSGI-HEV(I)] in the pSGI vector.
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tional) using a Hybri-slot manifold (Life Technologies). RNA from cells trans-
fected with plasmid pSGI was used as a negative control. In addition, the in
vitro-transcribed, unlabeled sense and antisense HEV RNAs (2.5 mg of each)
were used as positive and negative controls alternatively. Before transfer, the
manifold was cleaned with 0.1 M NaOH and rinsed twice with diethyl pyrocar-
bonate-treated water. The membrane was cut to the size of the manifold and
soaked in 203 SSC for 10 min prior to blotting. Approximately 30 mg of the total
RNA isolated from the HEV RNA-transfected cells was mixed with 3 volumes of
denaturing solution (5 ml of deionized formamide, 1.62 ml of 37% formaldehyde,
1 ml of MOPS buffer (0.2 M morpholinepropanesulfonic acid [MOPS], 0.5 M
sodium acetate, 0.01 M EDTA [pH 8.0]) and incubated at 65°C for 15 min. The
mixture was chilled on ice, diluted with 1 ml of ice-cold 203 SSC, and loaded into
defined wells. Suction was continued until the samples in all of the wells were
exhausted. The membrane was air dried, UV cross-linked, and incubated in
prehybridization solution as described above. Sense- and antisense-specific ribo-
probes were prepared by transcription with T7 and SP6 polymerases (Riboprobe
system-T7 and Riboprobe system-SP6; Promega) using direct and reverse-ori-
ented clones of an HEV cDNA encompassing nt 1 to 457 in pCR-Script SK(1)
(Stratagene) and pGEM-T (Promega) as vectors, respectively. The transcription
reaction was carried out in the presence of [a-33P]UTP (2,500 Ci/mmol; Amer-
sham International). Prior to in vitro transcription, the template DNA was
linearized by restriction enzyme digestion at the end of the fragment. The
reaction mixture was treated with DNase I, extracted with phenol-chloroform,
and ethanol precipitated as described above. The hybridization and washing
conditions used were similar to those described earlier. The thoroughly washed
membrane was wrapped in Saran Wrap and exposed to autoradiography.
Detection of viral proteins in transfected cells. The RNA-transfected cells
were lysed in 750 ml of radioimmunoprecipitation assay buffer (10 mM Tris-HCl
[pH 8.0], 140 mM NaCl, 5 mM iodoacetamide, 0.5% Triton X-100, 1% SDS, 1%
sodium deoxycholate, 2 mM phenylmethylsulfonyl fluoride). The clarified lysate
was incubated with 7 ml of anti-ORF2, anti-ORF3, or anti-ORF1 antibodies
(putative anti-methyltransferase [anti-met], putative anti-helicase [anti-hel], or
putative anti-RdRp, respectively) independently on ice for 1 h. The polyclonal
antibodies were raised in rabbits against the structural proteins (pORF2 and
pORF3) and components of nonstructural polyprotein pORF1 (putative meth-
yltransferase, helicase, and RdRp regions) as described elsewhere (2, 23). The
antigen-antibody complexes formed were further incubated with 100 ml of a 10%
suspension of preswollen protein A-Sepharose 4B (Pharmacia, Uppsala, Swe-
den), and the reaction mixture was kept at 4°C with slow end-to-end shaking.
After 1 h, the reaction mixture was centrifuged for 1 min at 10,000 rpm in a
refrigerated microcentrifuge (Hermle). The supernatant was discarded as radio-
active waste, and the beads were washed thrice with 1 ml of radioimmunopre-
cipitation assay buffer for 10 min at 4°C with shaking. The complex was boiled
with 50 ml of 23 SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer
(50 mM Tris-HCl [pH 6.8], 2% SDS, 5% 2-b-mercaptoethanol, 0.1% bromo-
phenol blue) and analyzed by SDS–6 to 15% gradient PAGE. The gel was treated
with 0.5 M sodium salicylate, washed, dried, and exposed to autoradiography as
described above.
For immunofluorescence studies, transfection was carried out on cells grown
on coverslips (30-mm diameter). After 72 h, the cells on the coverslips were
washed twice with phosphate-buffered saline (PBS, pH 7.2) and fixed with 4%
paraformaldehyde at room temperature for 30 min. Following fixation, the cells
were incubated with 0.1% saponin (Sigma) on ice for 10 min, washed with PBS,
and incubated with 1:100-diluted anti-pORF2, anti-pORF3, anti-met, and anti-
hel antibodies for 1 h in a humid chamber at 37°C. The cells were washed with
PBS and further incubated with a goat anti-rabbit fluorescein isothiocyanate
conjugate (1:100 dilution; Sigma) at 37°C in the humid chamber for 45 min. After
three washings with PBS, the coverslips were mounted on glass slides and ob-
served under a confocal microscope (Bio-Rad). Similarly, immunofluorescence
labeling of transfected cells with anti-RdRp antibody was carried out 24 h
posttransfection. Cells transfected with the vector pSGI served as a negative
control.
Experimental infection of rhesus monkeys. Ethical clearance was obtained
from the institutional primate research facility for experimentation on rhesus
monkeys. The animals (M-1690, M-1761, M-1927, and M-2197) were put under
quarantine, and any prior infections were ruled out. Preinoculation blood was
collected aseptically. The sera were analyzed for the presence of anti-HEV
immunoglobulin M (IgM), anti-HEV IgG, and HEV RNA by RT-PCR. Animals
negative for these markers were used for further experiments. One rhesus mon-
key (M-1690) was injected intravenously with 6 ml of pooled culture supernatants
from HEV RNA-transfected HepG2 cells collected at 72 h. The control monkey
(M-1761) was injected only with PBS and kept under the same conditions. Two
other monkeys (M-1927 and M-2197) were injected with 100 mg of in vitro-
transcribed HEV RNA with animal-injectable RNase inhibitor (Promega) in the
liver at multiple sites after performance of a minilaparotomy. After the inocu-
lation, blood samples were collected aseptically twice a week and serum was
stored at 270°C for further use. Alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) levels were monitored by using a commercial assay kit
(Boehringer GmbH, Mannheim, Germany). HEV antibodies were detected by
an in-house enzyme-linked immunosorbent assay system using recombinant
HEV proteins (pORF2, pORF3, and pORF1) (S. K. Panda, unpublished data).
The presence of HEV RNA was investigated by RT-PCR as described earlier
(13).
Nucleotide sequence accession number. The sequence of pSGI-HEV(I) was
submitted to GenBank and assigned accession no. AF076239.
RESULTS
Production of HEV transcripts. An HEV cDNA clone en-
compassing nucleotides 1 to 7195 with a 5-bp stretch of ade-
nine residues at its 39 end was reconstructed in a eukaryotic
expression vector (Fig. 1). In vitro transcription of this clone
generated a transcript of ;7.2 to 7.4 kb as determined by
denaturing agarose gel electrophoresis and Northern blot anal-
ysis. Most of the in vitro-transcribed material corresponded to
this RNA species, as shown by a comparison of the ethidium
bromide-stained and Northern blotted lanes (Fig. 2). Most of
the HEV transcripts were about 7.2 kb in size, corresponding
to the complete genome, when compared with standard RNA
molecular weight markers (Life Technologies). The resolved
RNA was blotted onto a nylon membrane, and Northern hy-
bridization with an HEV-specific probe confirmed the full-
length HEV transcripts (Fig. 2).
Detection of antisense replicative intermediate RNA. Both
the sense and antisense strands of the HEV genome were
detected by strand-specific RT-PCR in HEV RNA-transfected
HepG2 cells. The pSGI-transfected cells remained negative for
HEV sequences at all times. The HEV RNA-transfected cells
were positive for the sense and antisense strands of the HEV
genome at 3, 7, 15, and 33 days (data not shown). In the
experiment with serial log-fold dilutions carried out at 72 h
posttransfection, the negative-sense strand of the HEV ge-
nome was detected up to a dilution of 1026 of the total HepG2
cell RNA. On the other hand, the positive-sense strand was
detected up to a dilution of 10215 (Fig. 3a and b). The positive-
sense strand was more abundant than the negative-sense
strand.
To further confirm the presence of antisense RNA, a strand-
specific hybridization was carried out using [a-33P]UTP-la-
beled riboprobes. Both sense and antisense HEV RNAs could
be detected in transfected cells by this method, while control
cells transfected with the pSGI vector did not show any signal
on hybridization (Fig. 4). In vitro-synthesized sense and anti-
FIG. 2. Analysis of in vitro-transcribed full-length HEV RNA from the
cDNA clone [pSG-HEV(1)] by 0.8% formaldehyde agarose gel electrophoresis.
Lanes: 1, ethidium bromide-stained gel; 2, Northern hybridization using an
HEV-specific probe; M, RNA molecular size markers (in kilobases; Life Tech-
nologies).
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sense HEV RNAs were used to validate the specificity of the
hybridization method in detecting the strands. The presence of
antisense HEV RNA was reconfirmed by hybridization.
Detection of viral proteins in RNA-transfected cells. The
HEV ORF2 and ORF3 proteins (pORF2 and pORF3) were
detected by immunoprecipitation with the corresponding spe-
cific antibodies (Fig. 5a). pORF2 was detected as an ;72-kDa
protein by SDS–6 to 15% gradient PAGE followed by autora-
diography. A protein corresponding to pORF3 (;13.5 kDa)
was also immunoprecipitated from the transfected cells (Fig.
5a). The signals corresponding to the putative methyltrans-
ferase (;35 kDa), helicase (;38 kDa), and RdRp (;36 kDa)
domains could be detected by immunoprecipitation (Fig. 5b
and c). The putative helicase and methyltransferase were de-
tected in samples prepared at 72 h posttransfection. However,
the putative RdRp was detected only at 12, 24, and 36 h
posttransfection (Fig. 5c). It was not detected in transfected
cells at 72 and 96 h (data not shown). There were additional
unique high-molecular-weight bands in the immunoprecipita-
tion experiments using antibodies against the putative helicase
and methyltransferase domains. These may be intermediates in
the processing of the ORF1 protein (Fig. 5b). In all of the
immunoprecipitation experiments, pSGI-transfected HepG2
cells were used as a control and specific polypeptide species
were found to be missing from these control cells.
Fluorescent-antibody staining was carried out at 72 h post-
transfection with anti-pORF2, anti-pORF3, anti-met, anti-hel,
and anti-RdRp antibodies against the HEV proteins. In addi-
tion, staining for RdRp was performed at 24 h posttransfection
because of its absence at 72 h in the immunoprecipitation
experiments. Both the structural (pORF2 and pORF3) and
nonstructural proteins (corresponding to the putative domains
of Met, Hel, and RdRp) were demonstrated in the transfected
cells following staining with the corresponding antibodies (Fig.
6). None of the antibodies showed any significant signal with
control cells transfected with vector plasmid pSGI (Fig. 6).
HEV infection of Macaca mulatta following inoculation with
culture supernatant from RNA-transfected cells. The culture
supernatant from HEV RNA-transfected cells was used to
produce infection in a rhesus monkey (M-1690). Following
inoculation, HEV RNA was observed with the help of RT-
PCR in sera collected on days 24 to 37 (Fig. 7). During this
period (24 to 37 days), the AST and ALT levels increased to
1.5 to 2.5 (53 to 100 IU/liter) times normal levels. The IgM
class of anti-HEV antibodies directed against the ORF1,
FIG. 3. HEV genome amplification product resulting from strand-specific PCR carried out on total RNA extracted from HepG2 cells transfected with full-length,
positive-sense, in vitro-synthesized HEV RNA. (a) Detection of the negative-sense strand of HEV RNA. Lanes: M, marker (100-bp ladder; Life technologies); P,
positive control (RNA isolated from HEV-infected rhesus monkey liver); N, negative control (RNA extracted from bile fluid of a HEV-infected rhesus monkey); 1,
RNA (1 mg) extracted from HepG2 cells transfected with in vitro-synthesized HEV RNA at 72 h (neat); 2 through 9, log dilutions of transfected HepG2 cell RNA from
1021 through 1028. (b) Detection of the positive-sense strand of HEV RNA. Lanes: M, marker (100-bp ladder; Life Technologies); P, positive control (RNA extracted
from HEV-infected rhesus monkey serum); N, negative control (RNA extracted from normal control rhesus monkey serum); 1, RNA (1 mg) extracted from HepG2
cells transfected with in vitro-synthesized HEV RNA at 72 h; 2 through 8, log dilutions of total RNA from transfected HepG2 cells (2, 1021 dilution; 3, 1025 dilution;
4, 10210 dilution; 5, 10215 dilution; 6, 10216 dilution; 7, 10217 dilution; 8, 10218 dilution).
FIG. 4. Strand-specific slot blot hybridization for detection of positive- and
negative-sense HEV RNA in total RNA extracted from HepG2 cells transfected
with full-length, in vitro-transcribed HEV RNA. (A) Hybridization with
[a-33P]UTP-labeled riboprobe of antisense polarity. Slots: 1, In vitro-synthesized
positive-sense HEV RNA (positive control); 2, In vitro-synthesized negative-
sense HEV RNA (negative control); 3, RNA isolated from HepG2 cells trans-
fected with full-length, in vitro-transcribed HEV RNA; 4, RNA isolated from
HepG2 cells transfected with the pSGI vector as a control. (B) Hybridization
with [a-33P]UTP riboprobe of sense polarity: 1, In vitro-synthesized HEV RNA
of negative-sense polarity (positive control); 2, In vitro-synthesized HEV RNA of
positive-sense polarity (negative control); 3, RNA isolated from HepG2 cells
transfected with full-length, in vitro-transcribed HEV RNA; 4, RNA isolated
from HepG2 cells transfected with the pSGI vector as a control.
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ORF2, and ORF3 viral proteins were detected after 4 weeks
and persisted for the next 14 days. The ratios of optical density
between preinoculation and positive sera were in the range of
1:8 to 1:15, which is typical for HEV infection in rhesus mon-
keys. The animals (M-1927 and M-2197) which received in
vitro-produced HEV RNA, as well as the control monkey
(M-1761), remained normal, with no rise in ALT and AST
levels, and no seroconversion for antibodies was observed.
They also remained negative for HEV RNA in serum (vire-
mia) throughout the follow-up period. The anti-HEV IgG an-
tibodies were detected in the infected monkey (M-1690) 3
months after inoculation.
DISCUSSION
Infection due to HEV accounts for one-third of the sporadic
acute viral hepatitis and almost all of the described epidemics
on the Indian subcontinent (16, 22). It is a major health prob-
lem in tropical and subtropical parts of the world. The genome
of HEV has been cloned and sequenced from several different
geographical isolates (3, 12, 32, 33). However, the biology of
the virus is poorly understood due to the lack of a suitable
culture system. Recently, primary hepatocytes collected from
HEV-infected macaques have been successfully propagated
(31). However, this is time consuming and requires a suitable
experimental animal facility. The alternative approach is to
express the viral proteins in vitro, study their properties, and
thereby define their role in the viral life cycle. Our earlier
studies involved such a subgenomic expression strategy to char-
acterize HEV structural proteins pORF2 and pORF3 (14, 23,
36, 37). Complete nonstructural ORF1 and its putative func-
tional domains have been similarly reconstructed and ex-
pressed in prokaryotic and eukaryotic systems (2). These three
ORFs, originating from a single viral isolate, were joined in the
proper orientation to produce a full-length cDNA clone of
HEV, which was used to generate full-length HEV RNA. Such
in vitro-generated RNA was shown to be infectious in the
tissue culture system. This is similar to observations with the
other positive-stranded RNA viruses (9, 26, 28, 30).
Production of a replication- and transcription-competent
(infectious) clone will mitigate the difficulties in the analysis of
virus biology. For this purpose, the in vitro-produced full-
length HEV RNA was used to study the replication of the virus
via gene transfer. In this context, the HEV genome was cloned
downstream of the T7 promoter and transcribed in vitro, and
transcripts were characterized. The negative strand of viral
RNA usually serves as the replicative intermediate in most of
FIG. 5. (a) Autoradiograph showing immunoprecipitation of structural proteins from HEV RNA-transfected HepG2 cells. The arrows indicate signals in lanes 2
and 4 that represent pORF2 (;72 kDa) and pORF3 (13.5 kDa), respectively. pSGI-transfected cells were immunoprecipitated with anti-ORF2 and anti-ORF3
antibodies (lanes 1 and 3) to serve as controls. The immunoprecipitates were analyzed by SDS–6 to 15% gradient PAGE and visualized by fluorography. The molecular
sizes of 14C-labeled markers (in kilodaltons; Amersham International) are indicated on the right. (b) Autoradiograph showing immunoprecipitation of putative domains
of a nonstructural polyprotein corresponding to the methyltransferase and helicase from HEV RNA-transfected HepG2 cells. The arrows indicate signals in lanes 2
and 3 that represent the signals corresponding to the putative methyltransferase (;35 kDa) and helicase (;38 kDa), respectively. Mock-transfected pSGI cells were
immunoprecipitated with anti-met and anti-hel antibodies (lanes 1 and 4) to serve as controls. The immunoprecipitates were analyzed by SDS–6 to 15% gradient PAGE
and visualized by fluorography. Molecular size markers, in kilodaltons (Rainbow markers; Amersham International), are indicated on the right. (c) Autoradiograph
showing immunoprecipitation of putative domains of a nonstructural polyprotein corresponding to RdRp from HEV RNA-transfected HepG2 cells. The immuno-
precipitation was carried out using anti-RdRp antibodies at 12, 24, and 36 h posttransfection. For a control, HepG2 cells were transfected with the pSGI vector and
immunoprecipitated at 36 h with the same antibody. The immunoprecipitates were analyzed by SDS–6 to 15% gradient PAGE and visualized by fluorography.
Molecular size markers, in kilodaltons (Rainbow markers; Amersham International), are indicated on the right.
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the positive-stranded RNA viruses. Such a species was dem-
onstrated for HEV in transfected HepG2 cells, indicating ac-
tive viral replication. The antisense strand was found to be
present in a lower amount than the sense strand, as in other
positive-stranded virus systems (30). While the sense strand
was detected at up to a 10215 dilution of the template RNA,
the antisense strand was detected at up to a dilution of 1026.
This is possibly because the antisense pregenome tends to get
converted into the sense strand faster. In addition, some of the
RNA used for transfection may persist even after thorough
washing and may lead to the detection of a very high level of
the sense strand. In most of the positive-stranded RNA viruses,
the positive and negative strands are synthesized in an un-
equimolar ratio; i.e., the positive strand is produced in excess
of the negative strand (30). It is believed that this is due to the
variation in interaction of different cellular proteins and/or
RdRp involved in regulating the rate of initiation of viral RNA
synthesis from a positive- or negative-sense template. The viral
replication was detected in the cells for six passages (33 days).
Thereafter, neither the sense nor the antisense HEV RNA
could be detected (45 days).
For efficient productive infection, the viral genome has to
interact with several viral, as well as cellular, proteins. These
interactions determine the efficiency of replication, transcrip-
tion, and translation. Therefore the in vitro-produced viral
RNA transcript has to mimic the virion RNA as closely as
possible. The parameters which affect infection by gene trans-
fer are heterogeneity of the transcript population; the presence
of a point mutation and the sequences at the 59 and 39 ends,
i.e., a number of nonviral nucleotides; and the presence of a
cap structure at the 59 end and a poly(A) tail at the 39 end. The
problem of heterogeneity in the transcript population is mainly
due to the poor fidelity of RNA polymerase (1, 10). As a result,
it may hamper the infectivity of the transcripts (5). In our
experiments, this was circumvented by use of a large quantity
of RNA for transfection studies. The effect of nonviral se-
quences at the extreme ends of viral transcripts may also play
an important role, and it has been observed that 59 extensions
generally decrease or abolish infectivity whereas 39 extensions
are tolerated to a limited extent (5). The reduced infectivity of
dengue virus RNA transcripts due to the presence of nonviral
sequences at the 59 end has been reported, whereas nonviral
nucleotides at the 39 end of the dengue virus RNA transcript
did not abolish infectivity (18). In other positive-stranded RNA
viruses, such as poliovirus (34), hepatitis A virus (9), and Sind-
bis virus (28), the in vitro-produced infectious RNA from a
cDNA clone had additional 59 nonviral sequences. In these
cases, the infectivity was found to be lower than that of the
virion RNA. However, such a comparison was not possible in
the case of HEV because it is still not possible to culture this
virus. There was only one nonviral nucleotide at the 39 end of
our HEV clone following digestion of the cDNA clone with the
restriction enzyme XhoI prior to in vitro transcription. The
HEV transcript used in this study has 12 nonviral nucleotides
at the 59 end in addition to the complete viral genome (acces-
sion no. AF076239). These additional nucleotides in the tran-
script at the 59 (12 nt) and 39 (1 nt) ends did not abolish its
competence for replication, as observed in this study. Recently,
FIG. 6. Composite photograph showing immunofluorescent antibody stain-
ing of in vitro-synthesized HEV RNA-transfected HepG2 cells and control cells
transfected with the pSGI vector. Panels B, D, F, H, and K represent the
immunofluorescent staining of HEV-transfected HepG2 cells with anti-pORF2,
anti-pORF3, anti-met, anti-hel, and anti-RdRp antibodies, respectively. Panels
A, C, E, G, and J represent the immunostaining of control HepG2 cells with the
same antibodies corresponding to the test panel. All of the immunostaining was
carried out at 72 h posttransfection, except that with the anti-RdRp antibodies,
which was performed 24 h posttransfection.
FIG. 7. Agarose (2%) gel electrophoresis of RT-nested PCR products (343
bp) of the HEV genome amplified from the serum of infected rhesus monkey (M.
mulatta) M-1690. P, positive control; N, control monkey M-1761; M, 100-bp
DNA ladder (Life Technologies). Lanes 1 to 5 represent serum samples collected
from the animal on days 24, 28, 33, 37, and 43, respectively, postinjection. Arrow,
amplified fragments from HEV genome.
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the presence of a cap structure in the HEV genome has been
described (15). However, the present study demonstrated rep-
lication of HEV RNA without a cap structure. Therefore, it
may be presumed that the presence of a cap structure is not
obligatory for HEV genome replication.
The transfected viral genome was not only capable of rep-
lication but also expressed viral proteins in transfected cells
and released infectious virus into the culture supernatant, as
evaluated by experimental infection of a rhesus monkey.
Nearly 20% of the cells were transfected, as observed by im-
munofluorescence assay. The metabolically labeled viral pro-
teins were immunoprecipitated from transfected cells using
their respective antibodies derived from both structural and
putative nonstructural regions. The nonstructural polyprotein
components identified from the predicted homology to the
putative methyltransferase, helicase, and RdRp domains were
immunoprecipitated separately from the transfected cells. The
putative RdRp was detected at up to 36 h of transfection. This
is possible because it is an early protein and undergoes rapid
degradation. Therefore, no signal corresponding to RdRp
could be detected at 72 and 96 h. However, the other proteins,
which include the putative methyltransferase and helicase,
were detected at 72 h posttransfection. This indicates that the
protein product from the ORF1 region undergoes processing.
No processing of the ORF1 polyprotein (;186 kDa) was
observed in our earlier experiments with the expression of
HEV ORF1 (2). No processed putative functional proteins
could be individually identified either in an in vitro coupled
translation system or in HepG2 cells transfected with the
ORF1 gene. Incubation of the eukaryotic expression product
of ORF1 did not reveal any degradation over 24 h at 37°C (2).
However, the complete genome of HEV incorporating the
same ORF1 shows processed components that could be im-
munoprecipitated with putative domain-specific antibodies.
Therefore, it is predicted that processing of the nonstructural
polyprotein occurs only in the context of the complete virus
genome. The other viral proteins, either directly or indirectly
through cell-dependent mechanisms, may activate proteases
responsible for such processing. A putative protease domain
has been identified in the ORF1 gene based on sequence
comparison (17). However, this has not been characterized yet.
The possibility that the viral protease needs activation cannot
be ruled out. The ORF3 protein is a phosphoprotein that binds
to src homology domain III. It is phosphorylated by mitogen-
activated protein kinase. Therefore, this possibly can play a
role in protein phosphorylation (36). Whether this protein
alters the activity of any cellular or viral protease to initiate
polyprotein processing needs further investigation.
Inoculation of the culture supernatant from the RNA-trans-
fected cells was able to produce infection in one rhesus mon-
key. This was evidenced by a rise in serum transaminase, direct
detection of the viral genome, and the appearance of IgM, and
later IgG, anti-HEV antibodies in the serum of the inoculated
animal. This is possible only when intact virus is released into
the culture supernatant, as inoculation of in vitro-produced
HEV RNA did not produce infection. This method of gene
transfer is unique in the sense that it permits the recovery of an
infectious agent from cells transfected with in vitro-produced
RNA from an HEV cDNA clone generated by assembly of
PCR-amplified subgenomic fragments. Similar assembly of
PCR-amplified fragments has been described earlier (24). It
has always been believed that during PCR amplification, errors
in nucleotide incorporation lead to production of mutated
fragments that may not be functionally active. However, our
experience indicates that use of simple methods, like addition
of a proofreading enzyme (Pfu DNA polymerase; Stratagene)
during amplification, can avoid this problem. This model of
HEV gene transfer can now be used to facilitate studies on the
evolution, pathogenesis, and molecular biology of HEV and in
drug development studies relevant to the understanding and
control of HEV infection.
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